GlassScriptPhysician profile
Nasri N Ghaly
NPI 1063479939
$152,763.39
in general payments reported to CMS, 2019-2025
36 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $25K · 2021: $20K · 2022: $11K · 2023: $22K · 2024: $15K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Food and Beverage: $7,952 · Consulting Fee: $2,898 · Travel and Lodging: $2,039 · Education: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,200.00 |
| Food and Beverage | $7,951.56 |
| Consulting Fee | $2,897.50 |
| Travel and Lodging | $2,038.92 |
| Education | $332.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $69,017.88 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $33,667.81 | 2021-2025 | |
| Alkermes, INC. | $19,936.26 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Allergan, INC. | $14,280.57 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,650.86 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $2,834.55 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $1,433.80 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $1,174.43 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $845.99 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Jazz Pharmaceuticals INC. | $819.32 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $793.35 | 2019-2025 | Invega, Invega Sustenna, Spravato |
| Lundbeck LLC | $729.90 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $717.68 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $681.73 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $442.57 | 2024-2025 | Cobenfy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $440.25 | 2019-2025 | Perseris, Sublocade |
| Eisai INC. | $208.14 | 2019-2020 | |
| Bausch Health US, LLC | $176.21 | 2019-2023 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $132.68 | 2021-2025 | Loreev Xr |
| Corium, LLC | $131.48 | 2022-2025 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $84.86 | 2021 | |
| Shire North American Group INC | $79.72 | 2019 | |
| Biogen, INC. | $75.59 | 2024-2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $73.24 | 2022 | |
| Amgen INC. | $54.13 | 2019 | |
| Ironshore Pharmaceuticals INC. | $48.86 | 2019-2020 | |
| Alfasigma USA, INC. | $36.51 | 2020-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $34.79 | 2024 | Lumryz |
| Merck Sharp & Dohme LLC | $27.69 | 2019-2020 | |
| Adlon Therapeutics L.P. | $25.72 | 2020 | |
| Avanir Pharmaceuticals, INC. | $23.12 | 2019 | |
| Noven Therapeutics, LLC | $22.51 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.16 | 2022 | |
| Luye Pharma (USA) LTD. | $14.67 | 2025 | Erzofri Extended-Release |
| Pfizer INC. | $14.28 | 2023 | |
| Owp Pharmaceuticals, INC. | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasri Ghaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.